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Abstract: This study aimed to examine the association of relative handgrip strength (rHGS) with
cardiometabolic disease risk factors in women with systemic lupus erythematosus (SLE). Methods:
Seventy-seven women with SLE (mean age 43.2, SD 13.8) and clinical stability during the previous
six months were included. Handgrip strength was assessed with a digital dynamometer and rHGS
was defined as absolute handgrip strength (aHGS) divided by body mass index (BMI). We measured
blood pressure, markers of lipid and glucose metabolism, inflammation (high sensitivity C-reactive
protein [hs-CRP]), arterial stiffness (pulse wave velocity [PWV]), and renal function. A clustered
cardiometabolic risk index (z-score) was computed. Results: Pearson′s bivariate correlations revealed
that higher rHGS was associated with lower systolic blood pressure (SBP), triglycerides, hs-CRP, PWV,
and lower clustered cardiometabolic risk (rrange = from −0.43 to −0.23; all p < 0.05). Multivariable
linear regression analyses adjusted for age, disease activity (SLEDAI), and accrual damage (SDI)
confirmed these results (all p < 0.05) except for triglycerides. Conclusions: The findings suggest that
higher rHGS is significantly associated with lower cardiometabolic risk in women with SLE.
Keywords: autoimmune disease; cardiovascular risk; muscle strength; body mass index; metabolism;
cardiovascular disease; lupus; risk factors
1. Introduction
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease marked with
a wide variety of organ system dysfunctions, such as damage to joints, lungs, heart,
kidneys, brain, blood vessels or skin [1,2]. The SLE prevalence rates are 20 of every
100,000 women [3], and it affects women at a rate of 10:1 more than men [4]. Due to
improved diagnostic methods and treatments [5], mortality in SLE patients continues
to improve. However, cardiovascular and metabolic diseases are still one of the biggest
causes of mortality in SLE [6], and common risk factors cannot fully explain the increased
cardiometabolic risk in this population [7].
Traditional cardiometabolic risk factors including hypertension, diabetes, dyslipi-
demia, and smoking [8,9], and non-traditional cardiometabolic risk factors including
abdominal obesity, insulin resistance, lipid profile, arterial stiffness, renal markers, and
high-sensitivity C-reactive protein (hs-CRP; as a marker of inflammation [10,11]) lev-
els [8,12,13] are both expensive and difficult to measure outside a clinical environment [14].
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Furthermore, patients with SLE are usually treated with corticosteroids, which at high
doses interfere with lipid and glycemic metabolism [15].
Muscular strength is reduced in women with SLE [16,17], and low strength levels
are associated with higher fatigue, worse quality of life [18], and higher risk of cardio-
vascular disease and mortality [19,20]. Handgrip strength, a simple and quick method
to assess upper body muscular strength, is inversely associated with coronary heart dis-
ease [19,21], inflammation (which appears very often in SLE) [22], and mortality risk [23]
in the general population. In women with SLE, handgrip strength is negatively related to
obesity [13,17,19], and positively associated with quality of life [24].
Relative handgrip strength (rHGS), defined by the summation of both hands’ strength
divided by body mass index (BMI), is an easy instrument for measuring relative mus-
cular strength in clinical practice and public health [25] and has been recommended in
recent research to address the increased strength due to body mass [25–28]. Handgrip
strength and BMI have both been linked to cardiometabolic disease risk in the general
population [29–32], although the evidence regarding the association of rHGS with car-
diometabolic risk in women is scarce [26]. Since rHGS is cost- and time-efficient, it is
of clinical interest to understand the extent to which it might be associated with car-
diometabolic risk factors in a population at high risk of cardiometabolic diseases, such as
women with SLE.
The primary purpose of the current study was to examine the association of rHGS
with biomarkers of cardiometabolic disease risk in women with SLE.
2. Materials and Methods
2.1. Design and Participants
In this cross-sectional study, a total of 172 Caucasian patients with SLE were invited
to participate. Inclusion criteria were: (i) women aged between 18 and 60 years with
(ii) >4 SLE classification criteria provided by the American College of Rheumatology [33];
(iii) a minimum follow-up of one year at our unit; and (iv) clinical stability (i.e., the absence
of changes in the systemic lupus erythematosus disease activity index (SLEDAI) and/or
treatment) during the previous 6 months. Exclusion criteria were: (i) not being able to
read, understand, and/or sign the informed consent; (ii) having cancer; (iii) history of
clinical cardiovascular disease and/or lung disease in the last year; and (iv) receiving
doses of biological treatment higher than 10 mg/d of prednisone (or equivalent) in the
previous 6 months. All participants received detailed information about the study aims
and procedures and signed informed consent before being included in the study.
2.2. Measurement of Relative Handgrip Strength
Muscular strength was assessed through the handgrip strength test. The handgrip
strength test [34] was assessed using a digital dynamometer (Model T.K.K.540®; Takei
Scientific Instruments Co., Ltd., Niigata, Japan) with a precision to the nearest 0.1 kg.
Participants performed the trial in a standing position, with the elbow fully extended and
the arm relaxed in a neutral position and were encouraged by the evaluators to exert to their
maximal effort during a couple of seconds, alternating between the two hands. Participants
performed the test twice with a one-minute break between the two attempts of each hand.
The aHGS was summed from the best score of each hand. The rHGS was defined as aHGS
divided by BMI [25]. Height (cm) was measured using a stadiometer (SECA 222, Hamburg,
Germany) and weight (kg) with a bioimpedance device (InBody R20, Biospace, Seoul,
Korea). BMI was calculated as weight (kg) divided by height squared (m2).
2.3. Measurement of Cardiometabolic Risk Factors
Systolic blood pressure (SBP), diastolic blood pressure (DBP), and resting heart rate
were measured using the Mobil-O-Graph® 24 h pulse wave analysis monitor (IEM GmbH,
Stolberg, Germany) in a sitting position according to the European Society of Hyperten-
sion [35], after 5 min of rest.
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Arterial stiffness was indirectly assessed through the pulse wave velocity (PWV) [36].
The test was performed in a sitting position after 5 min of rest, using the Mobil-O-Graph®
24 h pulse wave analysis monitor, the operation of which is based on oscillometry recorded
by a blood pressure cuff placed on the brachial artery. This instrument is validated for
clinical practice [36]. PWV was obtained from a single measurement. The coefficient
of variation (CV) of the Mobil-O-Graph for consecutive PWV analyses is 3.4%, and its
intraclass correlation coefficient is 0.98 (0.96–0.99) [37].
Venous fasting blood samples were collected in the morning with heparin as the anti-
coagulant. Blood was centrifuged at 3500 rpm for 15 min to separate the plasma, which was
subsequently removed. Plasma triglycerides, high-density lipoprotein cholesterol (HDL-c),
low-density lipoprotein cholesterol (LDL-c), total cholesterol, glucose, urea, albumin and
creatinine concentrations were analyzed enzymatically with an autoanalyzer (Olympus
Diagnostic, Hamburg, Germany). Insulin was measured with an enzyme immunoassay
kit, and the homeostasis model assessment of insulin resistance (HOMA-IR) was calcu-
lated [(fasting insulin (µIU/mL) × fasting glucose (mg/dL))/405]. Apolipoproteins A
and B, hs-CRP, and glycosylated hemoglobin were determined by immunoturbidimetry
(HORIBA-ABX Diagnostics, Japan) with an autoanalyzer (PENTRA-400, HORIBA-ABX
Diagnostics, Japan). The albumin-creatinine ratio was measured from a first-morning urine
sample. Values above or equal to 30 mg/g in women were considered pathological. The
estimated glomerular filtration rate was determined by the modification of diet in renal
disease (MDRD) equation [38]: (GFe (MDRD)):
175 × SCr − 1.154 × age − 0.203 × 0.742
SCr: serum creatinine
2.4. Other Measurements
All participants filled out a sociodemographic and clinical data questionnaire to gather
information, such as age, disease duration, current medication (including antidiabetics
and corticosteroids), and tobacco consumption. The systemic lupus erythematosus disease
activity index (SLEDAI) was included to assess disease activity [39], considering the
presence or absence of several clinical and analytical manifestations in the preceding
10 days. The final score ranges from 0 to 105, where a higher score indicates a higher degree
of disease activity. The degree of tissue damage from the onset of the disease was evaluated
by the International Collaborating Clinics/American College of Rheumatology’s systemic
lupus damage index (SLICC-SDI) [40]. The score ranges from 0 to 40, where a higher score
indicates greater damage produced by SLE in the last 6 months.
2.5. Sample Size
The sample size was calculated for a clinical trial evaluating the effects of aerobic
exercise on arterial stiffness, inflammation, and fitness, which was published earlier [41].
We recruited 58 participants for that trial, although a larger sample (n = 77) was used to
perform baseline evaluations for cross-sectional analyses.
2.6. Statistical Analysis
The descriptive characteristics of the study participants are presented as means and
standard deviations for continuous variables, and as frequencies and percentages for cat-
egorical variables, unless otherwise indicated in Table 1. Due to the presence of outliers,
hs-CRP was winsorized. Normality was assessed through histograms, the Kolmogorov–
Smirnov Test, and Q–Q plots, with muscular strength and cardiometabolic risk factors
showing a normal distribution. Pearson’s bivariate correlations were used to explore
the raw association between rHGS and cardiometabolic risk factors, and we additionally
assessed the crude association of aHGS and BMI with cardiometabolic risk factors. Regres-
sion models were built including each cardiometabolic risk factor as dependent variables
in separate models. rHGS, age, SLEDAI, and SDI were entered as independent variables
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in all models (enter method). Age, SLEDAI, and SDI were entered as covariables due to
their potential role as confounders [42]. Menopause, statins or corticosteroids were initially
included, but they did not alter the coefficients, and thus they were not included in final
models to avoid overfitting [43].
Table 1. Descriptive characteristics of the study participants (n = 77).
Mean SD
Age (years) 43.2 1.57
Weight (kg) 65.1 1.27
Height (cm) 160.1 0.77
Body Mass Index (kg/m2) 25.5 0.51
Absolute Handgrip Strength (kg) 47.2 1.24
Relative Handgrip Strength (kg/BMI) 1.89 0.05
SLEDAI 0.6 0.17
Duration of SLE (years) 13.9 1.15
Systolic Blood Pressure (mmHg) 118 1.29
Diastolic Blood Pressure (mmHg) 76.5 1.18
Pulse Wave Velocity (m/s) 6.47 0.17
Fasting Glucose (mg/dL) 76.3 2.17
Glycosylated Hemoglobin (%) 5.31
High Density Lipoprotein (mg/dL) 57.8 1.57
Low Density Lipoprotein (mg/dL) 100.7 2.88
Total Cholesterol (mg/dL) 177.5 3.56
Triglycerides (mg/dL) 93.6 4.85
Homeostatic Model Assessment 1.45 0.09
hs-CRP (mg/L) 2.73 0.17
Glomerular Filtration (mL/min/1.73 m2) 92.6 3.33
Microalbuminuria (%) 28
Cumulative Prednisone dose (mg) 2875 2677
Daily Prednisone dose (mg) 3.99 0.57
Prednisone use (%) 65
Immunosuppressants (%) 45
Antimalarials (%) 89
For absolute and relative handgrip strength the total sample size was n = 75 due to missing data. SLEDAI:
systemic lupus erythematosus disease activity index; hs-CRP: high-sensitivity C-reactive protein.
A clustered cardiometabolic risk index (z-score) [12] was created using the mean
of the standardized scores [(value-mean)/standard deviation] for SBP, fasting glucose,
triglycerides, HOMA-IR, total cholesterol/HDL-c, and hs-CRP. Statistical significance was
set at p < 0.05.
3. Results
The flowchart of the study participants is presented in Figure 1. From a total of
172 patients initially invited, 81 refused to participate (41 patients reported living very far
from the hospital, 36 were not able to find time to perform the evaluations, and 4 were not
interested), 12 patients did not present clinical stability during the previous 6 months to
the beginning of the study, and 2 patients had cardiovascular disease during the previous
year. A total of 77 women with SLE (mean age 43.2, SD 13.8) complied with the inclusion
criteria, agreed to participate, and were assessed in two waves (49 women in October 2016
and 28 women in February 2017). Both evaluations were identical. Two women did not
perform the handgrip strength test due to a wrist injury.
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Figure 1. Flow diagram of the inclusion of women with systemic lupus erythematosus (SLE) for the present study.
The descriptive characteristics of the study participants are presented in Table 1.
The average BMI was 25.5 (SD 0.51) kg/m2. The average aHGS was 47.2 (SD 1.24) kg
nd for rHGS was 1 89 (SD 0.05) units. Regarding cardiometabolic risk variables, the
average SBP was 118 (SD 1.29) mmHg, the averag DBP wa 76.5 (SD 1.18) mmH , and
the average fasting glucose levels were 76.3 (SD 2.17) mg/dL. Average total c olesterol
was 177.5 (SD 3.56) mg/dL, the average hs-CRP levels were 2.73 (SD 0.35) mg/L and the
average PWV was 6.47 (SD 0.17) m/s.
Table 2 represents the raw association of rHGS, aHGS, and BMI with cardiometabolic
risk factors. rHGS was negatively associated with SBP, triglycerides, hs-CRP, PWV, and
z-score (rrange = from –0.43 to −0.23; all p < 0.05). aHGS was negatively associated
with triglycerides and PWV (rrange = from −0.34 to −0.23; all p < 0.05). Finally, BMI
was positively associated with SBP, DBP, fasting glucose, HOMA-IR, PWV, and z-score
(rrange = from 0.23 to 0.44; all p < 0.05). A graphic representation of the crude association
of rHGS and cardiometabolic risk factors is presented in Figure 2. The linear regression
models evaluating the association of rHGS and cardiometabolic risk factors are presented
in Table 3. rHGS was inversely associated with SBP (unstandardized coefficient (B) = −6.58;
95% confidence interval (CI) −11.91 to −1.26; p = 0.016), hs-CRP (B = −1.67; 95% CI −3.11
to −0.23; p = 0.023), PWV (B = −0.34; 95% CI −0.58 to −0.09; p = 0.007) and z-score
(B = −0.30; 95% CI −0.54 to −0.06; p = 0.014). These results were consistent even when
statins and corticosteroids were included as covariates.
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Table 2. Pearson’s bivariate correlations analysis evaluating the raw association between relative
handgrip strength, absolute handgrip strength and body mass index with cardiometabolic risk
components in women with systemic lupus erythematosus.
rHGS (n = 75) aHGS (n = 75) BMI
SBP −0.34 ** −0.15 0.40 **
DBP −0.13 0.01 0.32 **
Fasting Glucose −0.06 0.08 0.23 *
Glycosylated
Hemoglobin −0.13 −0.07 0.11
HDL 0.04 0.08 0.04
LDL 0.04 0.04 −0.00
Total Cholesterol 0.01 0.03 0.04
Triglycerides −0.28 * −0.23 * 0.15
HOMA-IR −0.15 0.11 0.43 **
hs-CRP −0.23 * −0.15 0.17
PWV −0.43 ** −0.34 ** 0.24 *
Glomerular Filtration 0.11 0.08 −0.10
Microalbumin 0.05 −0.04 −0.15
z−score −0.32 ** −0.09 0.44 **
SBP: systolic blood pressure; DBP: diastolic blood pressure; HDL: high-density lipoprotein; LDL: low-density
lipoprotein; HOMA-IR: homeostatic model assessment of insulin resistance; hs-CRP: high-sensitivity C-reactive
protein; PWV: pulse wave velocity. Notes: * p < 0.05; ** p < 0.01.
Table 3. Multivariable linear regression analysis evaluating the association of relative handgrip strength with cardiometabolic
risk components in women with systemic lupus erythematosus (n = 75).
Beta B Std Error 95% CI p R2
SBP −0.29 −6.58 2.67 −11.91 −1.26 0.016 0.20
DBP −0.10 −2.02 2.63 −7.27 3.23 0.445 0.03
Fasting
Glucose −0.09 −3.58 5.00 −13.55 6.39 0.476 0.01
Glycosylated
Hemoglobin −0.02 −0.02 0.11 −0.25 0.20 0.846 0.10
HDL 0.10 2.77 3.56 −4.33 9.89 0.438 0.02
LDL 0.16 8.06 6.08 −4.06 20.20 0.189 0.14
Total
Cholesterol 0.15 9.03 7.25 −5.44 23.50 0.218 0.18
Triglycerides −0.23 −19.41 10.50 −40.35 1.52 0.069 0.12
HOMA-IR −0.19 −0.34 0.22 −0.79 0.10 0.127 0.03
hs-CRP −0.29 −1.67 0.72 −3.11 −0.23 0.023 0.09
PWV −0.11 −0.34 0.12 −0.58 −0.09 0.007 0.91
Glomerular
Filtration −0.14 −7.68 5.75 −19.16 3.80 0.187 0.37
Microalbumin −0.11 −0.01 0.11 −0.23 0.21 0.925 0.10
z-score −0.30 −0.30 0.12 −0.54 −0.06 0.014 0.15
B: unstandardized coefficient; SBP: systolic blood pressure DBP: diastolic blood pressure; HDL: high-density lipoprotein; LDL: low-density
lipoprotein; HOMA-IR: homeostatic model assessment of insulin resistance; hs-CRP: high-sensitivity C-reactive protein; PWV: pulse wave
velocity. All regression models were adjusted for age, SLEDAI, and SDI. Regression models were built including each cardiometabolic risk
factor as dependent variables in separate models. Relative handgrip strength was entered as the independent variable in all models (enter
method) where age, SLEDAI, and SDI were entered as confounders in order to adjust the independent variable. Statistically significant
associations (p < 0.05) are highlighted in bold.
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4. Discussion
The main finding of this study is that a higher rHGS was associated with lower
SBP, triglycerides, hs-CRP, PWV, and clustered cardiometabolic risk index (z-score) in
women with SLE. Furthermore, rHGS could be an alternative to aHGS when evaluating
cardiometabolic risk. Our results were consistent despite adjusting for multiple potential
confounders such as age, SLEDAI, SDI, statins, menopause, smoking or corticosteroids.
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The association of aHGS and cardiometabolic risk has been previously studied in the
general population. Lee et al. [27] found that a higher aHGS was associated with lower car-
diovascular risk in older Korean adults. Similar findings were described by Leong et al. [21],
who found that aHGS was inversely associated with all-cause death in a prospective co-
hort study with 140,000 men and women. However, Gregorio-Arenas et al. [44] found
no association of aHGS with cardiometabolic risk in a sample of 228 perimenopausal
women. In line with this, Gubelmann, Vollenweider and Marques-Vidal [45] observed no
association between aHGS and cardiovascular risk in healthy adults. Regarding rHGS,
previous studies have assessed its association with cardiometabolic risk, although not in
rheumatological or autoimmune populations. Choquette et al. found that rHGS could be
an indicator of cardiometabolic risk in 1793 community-dwelling men and women [25].
Moreover, Lawman et al. [28] found that higher rHGS was significantly associated with
lower SBP, triglycerides, glucose, and higher HDL in both healthy men and women. Finally,
Campa et al. [46] demonstrated that resistance training is effective in improving both
cardiometabolic risk factors and rHGS in obese women, but improvements regarding rHGS
are only achieved if training frequency is high and prolonged over time [47]. Our results
are overall in line with these findings derived from other populations and extend current
knowledge on potential indicators of cardiometabolic risk in SLE, as well as agreeing with
recent literature.
The novel approach of this study is the concurrent analysis of the association of rHGS,
aHGS and BMI itself with cardiometabolic risk factors. Although no statistical test can
compare the strength of their independent association with the outcomes, these analyses
provide the opportunity to determine which of these markers of risk is more worthwhile in
clinical practice. Overall, rHGS and BMI were clearly better indicators of cardiometabolic
risk than aHGS. However, when comparing BMI with rHGS, the results were less clear.
While BMI was associated with markers of insulin resistance and the association with the
clustered cardiometabolic risk score was stronger than with rHGS, rHGS was more strongly
associated with arterial stiffness and, more importantly, with hs-CRP. As inflammation
is a hallmark of autoimmune diseases including SLE, these results should not be taken
into consideration when deciding whether to include the assessment of handgrip strength
in clinical practice. The relatively low sample size precludes making strong arguments
either in favor of or against this, although further research on this topic seems warranted.
In practical terms, it is obvious that BMI is the simplest way to obtain a strong marker of
cardiometabolic risk. However, it must be considered that adding a handgrip strength
assessment takes approximately 2 min (including double assessment of both hands), which,
depending on the context, might be feasible or not.
This study has potential limitations. Although other widely used tools to measure CV
risk have been proposed, these tools could underestimate CV risk in patients with SLE. Our
study provides a greater knowledge of CV risk using individual factors and a cluster score.
The cross-sectional design precludes the establishment of causal relationships; therefore,
our results must be corroborated in future prospective and experimental research. The
sample size was relatively small, and we do not know whether these results apply to men
or to women with medium or high disease activity, as only women with mild disease
activity were included.
5. Conclusions
The findings suggest that higher rHGS is significantly associated with lower car-
diometabolic risk in women with SLE. Although assessing rHGS might add relevant informa-
tion regarding the potential cardiometabolic risk of SLE patients, BMI alone is a rather good
indicator of cardiometabolic risk that might be preferred under time-constrained situations.
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